AMGN - Amgen Inc.
196.30 +0.65 (0.33%)
Pre-market: 7:26AM EDT
| Previous close | 195.04 |
| Open | 195.72 |
| Bid | 192.73 x 1000 |
| Ask | 196.40 x 1000 |
| Day's range | 194.58 - 196.37 |
| 52-week range | 166.30 - 211.90 |
| Volume | 1,199,157 |
| Avg. volume | 3,132,932 |
| Market cap | 117.331B |
| Beta (3Y monthly) | 0.80 |
| PE ratio (TTM) | 15.53 |
| EPS (TTM) | 12.60 |
| Earnings date | 28 Oct. 2019 - 1 Nov. 2019 |
| Forward dividend & yield | 5.80 (2.97%) |
| Ex-dividend date | 2019-08-14 |
| 1y target est | 214.84 |
- Simply Wall St.
Read This Before You Buy Amgen Inc. (NASDAQ:AMGN) Because Of Its P/E Ratio
The goal of this article is to teach you how to use price to earnings ratios (P/E ratios). We'll apply a basic P/E...
- Zacks
Alexion (ALXN) Down on News of CFO Clancy's Departure in 2019
Alexion's (ALXN) shares decline, following the news of the departure of its current chief financial officer, Paul Clancy.
- Zacks
Merck's Keytruda Combo Gets FDA Nod for Endometrial Carcinoma
Merck (MRK) receives accelerated approval for label expansion of Keytruda in combination with Lenvima for treating certain types of endometrial carcinoma. Its Ebola vaccine BLA gets priority review.
- Zacks
Biotech Stock Roundup: BIIB Halts AD Study, AMGN Posts Positive MM Drug Data & More
Key highlights of the past week include regulatory and pipeline updates, acquisition deals, and more.
- Zacks
Seattle Genetics' Enfortumab Vedotin BLA Gets Priority Review
The FDA accepts Seattle Genetics (SGEN) and Astellas' BLA for enfortumab vedotin under a priority review to treat advanced/metastatic urothelial cancer. A verdict is pending on Mar 15, 2020.
- Zacks
The Zacks Analyst Blog Highlights: Amgen, Tokyo Electron and Kinross Gold
The Zacks Analyst Blog Highlights: Amgen, Tokyo Electron and Kinross Gold
- Zacks
Alder (ALDR) Stock Up on Acquisition Agreement With Lundbeck
Alder (ALDR) signs an agreement to be acquired by Danish pharmaceutical company, Lundbeck A/S, for $1.95 billion.
- Zacks
Aimmune's Peanut Allergy Drug Gets FDA Committee's Support
Aimmune's (AIMT) peanut allergy drug gets majority of votes from the Advisory Committee of the FDA.
- Zacks
Amgen's Kyprolis Combo Improves PFS in Multiple Myeloma Study
Amgen's (AMGN) phase III study on Kyprolis in combination with dexamethasone and J&J's Darzalex meets the goal of progression-free survival for treating relapsed or refractory multiple myeloma.
- Zacks
Vertex Gains Reimbursement for Orkambi & Symkevi in Scotland
Vertex (VRTX) secures reimbursement nods in Scotland for its cystic fibrosis drugs Orkambi and Symkevi.
- Zacks
Celgene's (CELG) Leukemia Candidate Meets Endpoints in Study
Celgene's (CELG) CC-486 maintenance therapy improves overall survival in newly-diagnosed acute myeloid leukemia patients.
- Zacks
The Zacks Analyst Blog Highlights: Amgen, Cisco, Berkshire Hathaway, T. Rowe Price and McKesson
The Zacks Analyst Blog Highlights: Amgen, Cisco, Berkshire Hathaway, T. Rowe Price and McKesson
- Zacks
REGENXBIO (RGNX) Catches Eye: Stock Jumps 5.8%
REGENXBIO (RGNX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
- Zacks
Top Research Reports for Amgen, Cisco & Berkshire Hathaway
Top Research Reports for Amgen, Cisco & Berkshire Hathaway
- Zacks
Puma Biotech's sNDA for Nerlynx Combo Gets FDA Acceptance
The FDA accepts for review Puma Biotech's (PBYI) sNDA that seeks an approval for Nerlynx in combination with Roche's Xeloda for treating third-line breast cancer.
- Zacks
Ultragenyx to Submit sBLA for Label Expansion of Crysvita
Ultragenyx (RARE) and partner Kyowa Kirin plan to submit an sBLA to the FDA for the label expansion of Crysvita.
- Zacks
Biotech Stock Roundup: AMGN's Lung Cancer Candidate, ALXN's Deal With Eidos in Focus
Key highlights of the past week include regulatory and pipeline updates, and licensing deals and more.
- Zacks
Alexion (ALXN) In-licenses Amyloidosis Candidate In Japan
Alexion (ALXN) strengthens its amyloidosis portfolio with an exclusive license secured from Eidos to develop and commercialize an investigational small molecule AG10 in Japan.
- Zacks
Adaptimmune (ADAP) Gets Orphan Drug Status for T-cell Therapy
Adaptimmune Therapeutics (ADAP) gets Orphan Drug Designation for SPEAR T-cells targeting MAGE-A4 (ADP-A2M4 program) for the treatment of soft tissue sarcomas.
- Zacks
Horizon's (HZNP) Eye Disease Drug Gets FDA's Priority Review
Horizon (HZNP) announces the FDA has accepted the Biologics License Application (BLA) for teprotumumab, for the treatment of active thyroid eye disease, and granted it Priority Review designation.
- Investing.com
Amgen Falls 3%
Investing.com - Amgen (NASDAQ:AMGN) fell by 3.16% to trade at $195.92 by 10:53 (14:53 GMT) on Tuesday on the NASDAQ exchange.
- Zacks
Novartis Announces Positive Long-Term Data on Migraine Drug
Novartis' (NVS) migraine drug Aimovig is effective and safe in treating patients with episodic migraine in a long-term study.
- Zacks
Amgen's KRAS Inhibitor Shows Response in Larger NSCLC Group
Amgen's (AMGN) novel investigational KRAS inhibitor, AMG 510, for solid tumor shows anti-tumor activity in a larger group of NSCLC patients.
